Radioisotope synovectomy with rhenium186 in haemophilic synovitis for elbows, ankles and shoulders

Basit Öğe Kaydı
dc.contributor.authorKavakli K.
dc.contributor.authorAydogdu S.
dc.contributor.authorTaner M.
dc.contributor.authorDuman Y.
dc.contributor.authorBalkan C.
dc.contributor.authorKarapinar D.Y.
dc.contributor.authorSaydam, G..
dc.contributor.authorCapaci K.
dc.contributor.authorOktay A.
dc.date.accessioned2019-10-26T23:57:40Z
dc.date.available2019-10-26T23:57:40Z
dc.date.issued2008
dc.departmentEge Üniversitesien_US
dc.description.abstractWe have performed 221 radioisotope synovectomy (RS) in more than 150 children and young adults with haemophilia, age ranging 3-30years (mean 15) in Ege Hemophilia Center, Izmir, Turkey for last 7years. We always preferred to use Yttrium 90 (Y90) for knees; however, since 2005, we started using rhenium 186 (Re186) for medium-sized joints with respect to safety. In this article, we have evaluated long-term experience ranging from 6months to 3years (mean 18months) with Re186 for elbows (n = 35), ankles (n = 26) and shoulders (n = 2) in total of 63 RS procedures for 49 patients. Their age range was 3-30 years and mean age was 15.5. Two mCi of Re186 intra-articularly injected for treating target joints and chronical synovitis. After RS, joint bleedings were decreased for all patients. The best results were obtained for all joints in patients with grade-II synovitis as like earlier experience with Y90. Excellent rates (no bleeding) were observed in grade-II synovitis in 81% and 46% for elbows vs. 86% and 57% for ankles after 6months and after 1 year follow-up of patients, respectively. In grade-III synovitis, excellent rates were 53% and 25% for elbows and 44% and 29% for ankles, respectively. In five joints for five patients, repeated injections were needed for better outcome. No adverse events such as radioisotope leakage, local inflamatory reactions or malignancy development were observed during and after RS. For medium-sized joints, RS with Re186 seems to be either effective or safe treatment method. Our results confirm those previously published by others on the value of Re186 synoviorthesis in medium-sized joints in haemophilia patients. After this experience, we changed our protocol and we use Re 186 for all medium-sized joints for treating chronical synovitis. © 2008 Blackwell Publishing Ltd.en_US
dc.identifier.doi10.1111/j.1365-2516.2008.01691.xen_US
dc.identifier.endpage523en_US
dc.identifier.issn1351-8216
dc.identifier.issue3en_US
dc.identifier.pmid18371165en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage518en_US
dc.identifier.urihttps://doi.org/10.1111/j.1365-2516.2008.01691.x
dc.identifier.urihttps://hdl.handle.net/11454/21067
dc.identifier.volume14en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.relation.ispartofHaemophiliaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectChronic synovitisen_US
dc.subjectHaemophiliaen_US
dc.subjectRadioisotope synovectomyen_US
dc.subjectRhenium 186en_US
dc.subjectTarget jointen_US
dc.titleRadioisotope synovectomy with rhenium186 in haemophilic synovitis for elbows, ankles and shouldersen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu